Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26017756 | 0.82 | SNCA (0.54) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL21820325 | 0.82 | SNCA (0.54) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL28570456 | 0.81 | SNCA (0.46) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL21751996 | 0.71 | SNCA (0.58) | SNCAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL31334387 | 0.70 | ALDH1A1 (0.54) | MAPTLMNAALDH1A1GPR119 | |
| SCHEMBL1208152 | 0.70 | SNCA (0.86) | SNCAMAPTLMNAKDM4EGAA | |
| SCHEMBL29850622 | 0.70 | SNCA (0.86) | SNCAMAPTLMNAKDM4EGAA | |
| SCHEMBL21752128 | 0.69 | GPR119 (0.48) | SNCAMAPTLMNAALDH1A1GPR119 | |
| SCHEMBL26017758 | 0.69 | GPR119 (0.48) | SNCAMAPTLMNAALDH1A1GPR119 | |
| SCHEMBL4736392 | 0.67 | MAPT (0.65) | MAPTLMNAALDH1A1KDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112912376-A | Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases | 阿尔维纳斯运营股份有限公司 | 2021-06-04 | — | — | CN | disclosed |